Effectiveness of tenoxicam and ibuprofen for pain prevention following endodontic therapy in comparison to placebo: a randomized double-blind clinical trial

Access this Article

Search this Article

Author(s)

    • Arslan Hakan
    • Department of Restorative Dentistry and Endodontics, Faculty of Dentistry, Ataturk University
    • Topcuoglu Huseyin S.
    • Department of Restorative Dentistry and Endodontics, Faculty of Dentistry, Ataturk University
    • Aladag Halit
    • Department of Restorative Dentistry and Endodontics, Faculty of Dentistry, Ataturk University

Abstract

Tenoxicam is an effective analgesic and anti-inflammatory agent for symptomatic treatment of various conditions. The purpose of this study was to evaluate clinically the effectiveness of prophylactic tenoxicam and prophylactic ibuprofen in reducing post-endodontic pain compared with placebo. A total of 48 patients consented to a double-blind, single dose, prophylactic oral administration of 20 mg of tenoxicam, 200 mg of ibuprofen, or a placebo before root canal treatment. The root canal treatment was performed in one visit. The patients registered their degree of discomfort on a 100-mm visual analog scale, immediately postoperative, and 6, 12, 24, 48 and 72 h after initiation of root canal treatment. The two-way ANOVA test and Tukey HSD post hoc test showed that in the 6-h period, both 20 mg of tenoxicam and 200 mg of ibuprofen provided significantly better pain relief than the placebo. Prophylactic administration of a single dose of 20 mg tenoxicam or 200 mg ibuprofen before RCT provides an effective reduction at 6 h (<I>P</I> < 0.05). Because of the advantages of tenoxicam, it may be useful as a prophylactic analgesic when post-endodontic pain is anticipated. (J Oral Sci 53, 157-161, 2011)

Journal

  • Journal of Oral Science

    Journal of Oral Science 53(2), 157-161, 2011

    Nihon University School of Dentistry

Codes

  • NII Article ID (NAID)
    130000834354
  • Text Lang
    ENG
  • ISSN
    1343-4934
  • Data Source
    J-STAGE 
Page Top